Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with influenza A(H1N1) 2009 and influenza B viruses

Pediatric Infectious Disease Journal

Volumn 31, Issue 9, 2012, Pages 899-905

  Rath, Barbara ^a   Von Kleist, Max ^b   Tief, Franziska ^a   Karsch, Katharina ^a   Tuerk, Ewelina ^a   Muehlhans, Susann ^a   Louis, Florian ^c   Skopnik, Heino ^c   Schweiger, Brunhilde ^d   Duwe, Susanne ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Klinikum Worms   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

clearance; infants; influenza; oseltamivir; resistance

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; FOLLOW UP; GENOTYPE; HUMAN; INFLUENZA A (H1N1); INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; NASOPHARYNX; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; FEVER; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; KAPLAN-MEIER ESTIMATE; MALE; OSELTAMIVIR; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84865478417     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31825c7304     Document Type: Article

References (39)

1. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis. 2006;194(suppl 2):S133-S138.
2. Bhat N, Wright JG, Broder KR, et al. Influenza Special Investigations Team. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-2567.
3. Presanis AM, De Angelis D, Hagy A, et al. New York City Swine Flu Investigation Team. The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med. 2009;6:e1000207.
4. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. WHO Working Group for Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011;8:e1001053.
5. Fiore AE, Fry A, Shay D, et al. Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-24.
6. Centers for Disease Control. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-10 season. 2009. Available at: http://www.cdc.gov/H1N1flu/recommendations. htm. Accessed August 9, 2011.
7. Kimberlin DW, Shalabi M, Abzug MJ, et al. NIAID Collaborative Antiviral Study Group. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J. 2 010;29:195-198.
8. Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J. 2010;29:495-498.
9. Bautista E, Chotpitayasunondh T, Gao Z, et al. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708-1719.
10. World Health Organization. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses 2010. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1-use-antivirals- 20090820/en/index.html. Accessed August 09, 2011.
11. Harper SA, Bradley JS, Englund JA, et al. Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003-1032.
12. World Health Organization-EURO: Seasonal influenza-key issues for case management of severe disease. Available at: http://www.euro.who.int/-data/ assets/pdf-file/0008/130859/H1N1-key-issues-case-mgt-update.pdf. Accessed January 11, 2012.
13. Cao B, Li XW, Mao Y, et al. National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009;361:2507-2517.
14. Lee CK, Lee HK, Loh TP, et al. Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads, Singapore. Emerging Infect Dis. 2011;17:287-291.
15. Giannella M, Alonso M, Garcia de Viedma D, et al. Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect. 2011;17:1160-1165.
16. Li IW, Hung IF, To KK, et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest. 2010;137:759-768.
17. Li CC, Wang L, Eng HL, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerging Infect Dis. 2010;16:1265-1272.
18. Killingley B, Greatorex J, Cauchemez S, et al. Virus shedding and environmental deposition of novel A (H1N1) pandemic influenza virus: interim findings. Health Technol Assess. 2010;14:237-354.
19. Suess T, Buchholz U, Dupke S, et al. Robert Koch Institute Shedding Investigation Group. Shedding and transmission of novel influenza virus A/H1N1 infection in households-Germany, 2009. Am J Epidemiol. 2010;171: 1157-1164.
20. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48:389-396.
21. Duwe SC, Wedde M, Birkner P, et al. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany. Antiviral Res. 2011;89:115-118.
22. World Health Organization. Summary of influenza antiviral susceptibility surveillance findings, September 2010-March 2011.June 6 2011. Available at: http://www.who.int/influenza/gisrs
23. Rath B, Tuerk E, Karsch K, et al. Simultaneous influenza and RSV rapid testing in infants and children with influenza-like illness (Charité Influenza-Like Disease = ChILD Cohort). The Fourth ESWI Conference. Lavetta, Malta; 2011.
24. German Society for Pediatric Infectious Diseases (DGPI). [Aktualisierte Empfehlung der DGPI zur Diagnostik, Therapie und Prophylaxe der Infektion mit dem Neuen Influenza A/H1N1-Virus bei Kindern und Jugendlichen] 20 August 2009. Available at: http://www.dgpi.de/pdf/Influenza-A-H1N1-DGPI-Empfehlungen- 20Aug2009.pdf. Accessed August 09, 2011.
25. World Health Organization. Clinical management of human infection with pandemic (H1N1) 2009: revised guidance 2009. Available at: http://www. who.int/csr/resources/publications/swineflu/clinical-management-h1n1. pdf. Accessed August 9, 2011.
26. Ngaosuwankul N, Noisumdaeng P, Komolsiri P, et al. Influenza A viral loads in respiratory samples collected from patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses. Virol J. 2010;7:75.
27. Duchamp MB, Casalegno JS, Gillet Y, et al. Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful? Clin Microbiol Infect. 2010;16:317-321.
28. Schulze M, Nitsche A, Schweiger B, et al. Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR. PLoS ONE. 2010;5:e9966.
29. Biere B, Bauer B, Schweiger B. Differentiation of influenza B virus lineages Yamagata and Victoria by real-time PCR. J Clin Microbiol. 2010;48:1425-1427.
30. Potier M, Beauregard G, Bélisle M, et al. Neuraminidase activity in the mucolipidoses (types I, II and III) and the cherry-red spot myoclonus syndrome. Clin Chim Acta. 1979;99:97-105.
31. Casalegno JS, Frobert E, Escuret V, et al. Beyond the influenza-like illness surveillance: the need for real-time virological data. Euro Surveill. 2011;16:19756.
32. Meijer A, Jonges M, Abbink F, et al. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res. 2011;92:81-89.
33. Yang JR, Huang YP, Lin YC, et al. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Antiviral Res. 2010;88:256-262.
34. Hurt AC, Barr IG. Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children. Commun Dis Intell. 2008;32:57-62.
35. Lackenby A, Moran Gilad J, Pebody R, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill. 2011;16:19784.
36. Bastien N, Gubbay JB, Richardson D, et al. Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs. J Clin Microbiol. 2011;49:4020-4021.
37. Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerging Infect Dis. 2011;17:255-257.
38. Williams CJ, Schweiger B, Diner G, et al. Seasonal influenza risk in hospital healthcare workers is more strongly associated with household than occupational exposures: results from a prospective cohort study in Berlin, Germany, 2006/07. BMC Infect Dis. 2010;10:8.
39. Papenburg J, Baz M, Hamelin MÈ, et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis. 2010;51:1033-1041.